Diagnosing Skin Cancer in 2026: Why Neoplastic Dermatopathology Demands a New Edition
Skin cancer is the most commonly diagnosed malignancy worldwide. Melanoma incidence has increased by more than 50% over the past two decades. Merkel cell carcinoma — rare but lethal — is rising in parallel with the ageing population. Cutaneous lymphomas present in ways that overlap with benign inflammatory conditions, generating misdiagnosis rates that remain unacceptably high in non-specialist centres. And molecular pathology has transformed the way oncologists think about prognosis and treatment response for virtually every category of skin malignancy.
In this environment, any pathologist or dermatopathologist working without an up-to-date neoplastic dermatopathology reference is carrying unnecessary diagnostic risk. Diagnostic Pathology: Neoplastic Dermatopathology, 4th Edition (Elsevier, May 2026), by David S. Cassarino and Christine J. Ko, provides the field's most comprehensive updated reference — 1,048 pages covering the full spectrum of cutaneous tumours, from common keratinocyte carcinomas to rare mesenchymal neoplasms, with the molecular and immunohistochemical depth the current clinical landscape demands.
The Scale of the Diagnostic Challenge
The fourth edition arrives at a moment when the complexity of neoplastic dermatopathology has genuinely outpaced the previous edition's scope. BRAF, NRAS, and KIT mutation profiling are now routine in melanoma workup. PD-L1 expression testing influences treatment decisions across multiple cutaneous malignancies. The 2022 WHO Classification of Skin Tumours introduced new entities, revised existing ones, and reorganised the molecular underpinning of several tumour categories. A reference that does not incorporate these changes is not current — and in oncology, currency is a patient safety issue.
Cassarino and Ko have structured this edition to address those changes systematically, not as addenda but as integrated updates throughout the classification framework.
Melanoma: The Diagnostic Priority
The melanoma chapters are the heart of the book, and they reflect the field's transformation over the past five years. The classification of melanocytic lesions — always contested terrain — has been updated in line with the WHO 2022 framework and current ISdermpath consensus. The treatment of spitzoid neoplasms, ambiguous melanocytic tumours, and the entity formerly known as MELTUMP receives careful attention, with explicit guidance on when molecular ancillary testing changes the diagnostic conclusion and when it does not.
For pathologists interpreting sentinel lymph node biopsies or advising on the significance of ambiguous primary lesions, this clarity is operationally critical. The book does not shy away from diagnostic uncertainty — it provides the framework to navigate it.
Beyond Melanoma: The Full Spectrum
The volume covers keratinocyte carcinomas (basal cell and squamous cell) with the clinical depth they deserve — including the increasingly important category of high-risk cSCC in immunosuppressed patients, where misclassification has direct consequences for adjuvant therapy decisions. Merkel cell carcinoma, primary cutaneous lymphomas, adnexal tumours, and soft tissue tumours of the skin each receive dedicated sections with updated molecular correlates and differential diagnosis frameworks.
The immunohistochemistry panels presented throughout have been validated against current reagent availability and are presented in a format — tiered by diagnostic priority — that reflects actual laboratory workflow, not theoretical completeness.
For Oncology-Adjacent Pathology Departments
The growth of checkpoint inhibitor therapy has created a new interface between oncology and pathology that this edition addresses directly. Tumour mutational burden, microsatellite instability testing, and PD-L1 scoring in cutaneous malignancies are presented with the precision required for multidisciplinary oncology team discussions. For hospital pathology departments serving oncology units, this is the reference that makes those conversations possible.
Who Should Have This Book
- Hospital pathology department libraries, particularly those with oncology or dermatology affiliations
- Medical school libraries with pathology, dermatology, or oncology programmes
- Dermatopathology fellowship programmes
- Research units working on melanoma biology, cutaneous oncology, or molecular skin pathology
- Multidisciplinary oncology teams at tertiary centres with significant skin cancer volume
Price includes worldwide shipping. Available now.
Q&A
What molecular markers are now routinely used in the diagnosis and management of melanoma?
The core molecular panel in melanoma currently includes BRAF V600 mutation testing (which determines eligibility for targeted therapy with BRAF and MEK inhibitors), NRAS and KIT mutation testing (relevant for targeted therapy in specific melanoma subtypes), and assessment of tumour mutational burden and microsatellite instability (which predict response to checkpoint inhibitor immunotherapy). FISH analysis for chromosomal gains and losses remains important in the workup of ambiguous melanocytic lesions where conventional histology is insufficient for classification.
How has the WHO 2022 Classification of Skin Tumours changed dermatopathology practice?
The 2022 WHO classification introduced several important changes: it incorporated molecular data into the classification of melanocytic neoplasms at a level not seen in previous editions, it formally recognised new entities including those defined primarily by genetic alteration, and it revised the terminology of several historically contested entities. The classification emphasises the integration of histological and molecular findings as complementary — neither alone is sufficient for optimal classification of many tumour types.
What distinguishes high-risk cutaneous squamous cell carcinoma from standard risk?
High-risk cSCC is defined by features that predict elevated rates of local recurrence, nodal metastasis, and disease-specific mortality. These include tumour diameter greater than 2 cm, depth beyond 6 mm or invasion of subcutaneous fat, poorly differentiated or undifferentiated histology, perineural invasion, location on the ear or non-hairbearing lip, and occurrence in immunosuppressed patients. Patients with high-risk cSCC require multidisciplinary management including consideration of adjuvant radiation and, in some cases, PD-1 inhibitor therapy.
How are cutaneous lymphomas differentiated from benign inflammatory conditions?
The distinction between cutaneous T-cell lymphoma — particularly early mycosis fungoides — and benign inflammatory conditions is one of the most challenging diagnostic problems in dermatopathology. Accurate diagnosis requires integration of clinical history, histological pattern with attention to epidermotropism and lymphocyte cytology, immunohistochemical profiling, and T-cell receptor gene rearrangement studies. Multiple biopsies over time are often necessary.
What is the role of sentinel lymph node biopsy interpretation in melanoma management?
Sentinel lymph node biopsy is standard staging for melanoma patients at elevated risk of nodal spread. Pathological interpretation requires careful sectioning protocols, H&E assessment for macrometastases and micrometastases, and immunohistochemical confirmation with melanocyte markers. The clinical significance of submicrometastatic deposits remains an active area of investigation, with ongoing trials evaluating whether such findings change management decisions. Accurate and standardised pathology reporting is essential for data comparability across centres.
CLNZ Books is a specialist academic and professional bookseller headquartered in Auckland, New Zealand. We curate titles across Law, Economics & Finance, Energy, and Medicine for university libraries, research centres, hospitals, and professional institutions worldwide. Every title is personally selected. All prices include worldwide shipping via international courier.
clnzbooks.com | info@clnzbooks.com